Clinical Trial Update: REDO-JAK: Dose Reduction of Janus Kinase Inhibitors in Patients With Inflammatory Rheumatic Diseases [Phase 4]

View source ↗

Summary

Phase 4 trial assessing dose reduction of Janus kinase inhibitors in inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and axia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• JAK inhibitors (Janus kinase inhibitors)

Snippet

Sponsor: Sint Maartenskliniek | Conditions: Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | Phase 4 | Status: RECRUITING